Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
ProKidney Stock Quote

ProKidney (NASDAQ: PROK)

$2.12
(-21.8%)
-$0.59
Price as of April 26, 2024, 4:00 p.m. ET

ProKidney Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
PROK -78.35% -79%
S&P +23.33% +73.48% +11.63% +19%

ProKidney Company Info

ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease (CKD), shifting the emphasis away from management of kidney failure, to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells (SRCs) prepared from a patient’s own, autologous, renal cells. The company is headquartered in Winston-Salem, NC.

News & Analysis

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.